Julia Glade-Bender
Overview
Explore the profile of Julia Glade-Bender including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pearson A, Dubois S, Macy M, de Rojas T, Donoghue M, Weiner S, et al.
Eur J Cancer
. 2024 Jun;
207:114145.
PMID: 38936103
Phosphatidylinositol 3-kinase (PI3-K) signalling pathway is a crucial path in cancer for cell survival and thus represents an intriguing target for new paediatric anti-cancer drugs. However, the unique clinical toxicities...
2.
Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200334.
PMID: 36996377
Purpose: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic...
3.
Dubois S, Krailo M, Glade-Bender J, Buxton A, Laack N, Randall R, et al.
J Clin Oncol
. 2023 Jan;
41(11):2098-2107.
PMID: 36669140
Purpose: Monoclonal antibodies directed against insulin-like growth factor-1 receptor (IGF-1R) have shown activity in patients with relapsed Ewing sarcoma. The primary objective of Children's Oncology Group trial AEWS1221 was to...
4.
Meric-Bernstam F, Ford J, ODwyer P, Shapiro G, McShane L, Freidlin B, et al.
Clin Cancer Res
. 2023 Jan;
29(8):1412-1422.
PMID: 36662819
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on...
5.
Sabnis H, Shulman D, Mizukawa B, Bouvier N, Zehir A, Fangusaro J, et al.
J Clin Oncol
. 2021 Sep;
39(34):3822-3828.
PMID: 34591650
Purpose: The US Food and Drug Administration-expanded access program (EAP) uses a single patient use (SPU) mechanism to provide patient access to investigational agents in situations where no satisfactory or...
6.
Dubois S, Krailo M, Buxton A, Lessnick S, Teot L, Rakheja D, et al.
Arch Pathol Lab Med
. 2021 Mar;
145(12):1564-1568.
PMID: 33769463
Context.—: Molecular diagnostics play an increasing role in the diagnosis of Ewing sarcoma. The type of molecular testing used in clinical practice has been poorly described. Objective.—: To describe patterns...
7.
Hipp S, Goldman S, Kaushal A, Krauze A, Citrin D, Glod J, et al.
J Neurooncol
. 2020 Oct;
149(3):437-445.
PMID: 33040274
Purpose: This study was performed to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of the immunomodulatory agent, lenalidomide, when administered daily during 6 weeks of...
8.
Gampel B, Troullioud Lucas A, Broglie L, Gartrell-Corrado R, Lee M, Levine J, et al.
Pediatr Blood Cancer
. 2020 Jun;
67(9):e28420.
PMID: 32588957
No abstract available.
9.
Mody R, Yu A, Naranjo A, Zhang F, London W, Shulkin B, et al.
J Clin Oncol
. 2020 Apr;
38(19):2160-2169.
PMID: 32343642
Purpose: The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with relapsed/refractory neuroblastoma in the randomized Children's Oncology Group ANBL1221 trial. To more accurately...
10.
Burke M, Kostadinov R, Sposto R, Gore L, Kelley S, Rabik C, et al.
Clin Cancer Res
. 2020 Jan;
26(10):2297-2307.
PMID: 31969338
Purpose: Treatment failure from drug resistance is the primary reason for relapse in acute lymphoblastic leukemia (ALL). Improving outcomes by targeting mechanisms of drug resistance is a potential solution. Patients...